Cell survival has been closely linked to both trophic growth factor signaling and cellular metabolism. Such couplings have obvious physiologic and pathophysiologic implications, but their underlying molecular bases remain incompletely defined. As a common mediator of both the metabolic and anti-apoptotic effects of growth factors, the serine/threonine kinase Akt -also known as protein kinase B or PKB -is capable of regulating and coordinating these inter-related processes. The glucose dependence of the antiapoptotic effects of growth factors and Akt plus a strong correlation between Akt-regulated mitochondrial hexokinase association and apoptotic susceptibility suggest a major role for hexokinases in these effects. Mitochondrial hexokinases catalyse the first obligatory step of glucose metabolism and directly couple extramitochondrial glycolysis to intramitochondrial oxidative phosphorylation, and are thus well suited to play this role. The ability of Akt to regulate energy metabolism appears to have evolutionarily preceded the capacity to control cell survival. This suggests that Akt-dependent metabolic regulatory functions may have given rise to glucose-dependent antiapoptotic effects that evolved as an adaptive sensing system involving hexokinases and serve to ensure mitochondrial homeostasis, thereby coupling metabolism to cell survival. We hypothesize that the enlistment of Akt and hexokinase in the control of mammalian cell apoptosis evolved as a response to the recruitment of mitochondria to the apoptotic cascade. The central importance of mitochondrial hexokinases in cell survival also suggests that they may represent viable therapeutic targets in cancer.
Introduction
Apoptosis is an evolutionarily conserved multistep process critical for the normal development and homeostasis of mammalian tissues (Danial and Korsmeyer, 2004) . Dysregulated apoptosis is also widely accepted as a major contributor to the pathogenesis and progression of cancer and other disease. Much of our present understanding of apoptotic effectors and control mechanisms come from studies of developmentally regulated programmed cell death in the nematode Caenorhabditis elegans (Horvitz, 2003) . The apoptotic cascade, which is conserved in mammals and nematodes, is comprised of three principal regulators. The caspases, which constitute the executioners of apoptosis in mammalian cells, are orthologues of Ced-3 in C. elegans. Apaf1, which initiates mammalian caspase activation, is the corresponding orthologue of C. elegans Ced-4, and the mammalian antiapoptotic B-cell lymphoma-2 (Bcl-2) family proteins represent orthologues of C. elegans Ced-9, These antiapoptotic Bcl-2 family members possess four structurally conserved Bcl-2 homology (BH) domains (BH1-4), with BH4 being specifically required for antiapoptotic activity. Mammalian cells also express a large family of proapoptotic proteins that possess only a BH3 domain -hence the designation 'BH3-only' proteins. These proteins, which are orthologues of Egl-1 in C. elegans, specifically heterodimerize with their antiapoptotic Bcl-2 family counterparts. Unlike the situation in C. elegans, the mammalian Ced-4 orthologue, Apaf1, requires a co-factor for its activation. This cofactor is cytochrome c, which normally resides in the inter-membrane space (IMS) of mitochondria. Mammalian cells also express a unique proapoptotic subfamily of Bcl-2-like proteins, not found in C. elegans that contain three Bcl-2 homology domains (BH1-3). When activated, the prototypic members of this subfamily Bax and Bak homo-oligomerize at the outer mitochondrial membrane (OMM) and promote membrane permeability changes that culminate in the release of apoptogenic factors, including cytochrome c, from the mitochondrial IMS. The 'BH3 only' proteins participate in this process by directly activating and favoring the oligomerization of Bax and Bak at the OMM. These effects are directly antagonized in turn by homologous antiapoptotic proteins such as Bcl-2 and Bcl-x L , which heterodimerize with 'BH3 only' proteins, as well as with Bax and Bak, to prevent apoptosis through their sequestration. The intrinsic apoptotic cascade in mammals thus differs fundamentally from that in C. elegans by virtue of this obligate regulated mitochondrial involvement. Thus, in addition to their role as the principal energy generating system in respiring cells, mammalian mitochondria contain compartmentalized apoptogenic factors, including cytochrome c, that initiate the intrinsic apoptotic cascade when released from the confines of the OMM. Cytochrome c is particularly important in this regard, as it is a required co-factor, along with ATP for Apaf1 activation, apoptosome formation, and activation of the intrinsic caspase cascade. As such, mitochondria occupy a central position in mammalian apoptosis, but require OMM compromise or cytochrome c-conducting pore formation -such as occurs following Bax or Bak activation -to participate in this process. The requirement for OMM permeabilization in apoptosis and the roles of Bcl-2 family members in this process have been extensively reviewed elsewhere (Newmeyer and Ferguson-Miller, 2003; Breckenridge and Xue, 2004; Danial and Korsmeyer, 2004; Garrido and Kroemer, 2004; Jiang and Wang, 2004; Lucken-Ardjomande and Martinou, 2005a, b) .
Analogous to the apoptotic cascade, the principal regulators of Akt are highly conserved across species. The most preserved feature of the Akt signaling pathway, which has been genetically delineated in species as phylogenetically diverse as mammals and nematodes, is the capacity to regulate metabolism and maintain cellular energy homeostasis. In mammals, this pathway plays a major role in preventing apoptosis and promoting cell survival, whereas no such role has been established in C. elegans. We have previously proposed that this fundamental difference, in combination with a more widely conserved role for Akt signaling in regulating energy metabolism, suggests an evolutionary basis for the enlistment of Akt in the control of apoptosis that parallels the recruitment of mitochondria to the apoptotic cascade (Robey and Hay, 2005b) . In support of this hypothesis, Akt has been shown to promote mitochondrial integrity and inhibit cytochrome c release following an apoptotic stimulus, but the presence of a phosphorylatable hexose, such as glucose or 2-deoxyglucose, is a prerequisite for this effect (Gottlob et al., 2001; Plas et al., 2001; Rathmell et al., 2003) . Glucose uptake and metabolism are widely recognized as important determinants of cell survival and have been implicated in the modulation of programmed cell death in diverse cell types and systems (Moley and Mueckler, 2000) . The observations above and the reported ability of mitochondrial hexokinases to directly couple glycolysis to oxidative phosphorylation prompted us to specifically examine mitochondrial hexokinases as potential downstream effectors of Aktmediated cell survival. The emerging role of mitochondrial hexokinases in apoptosis is the principal focus of this review.
Hexokinases

Overview
Hexokinases play a vital role in the cellular uptake and utilization of glucose. As such, they are of fundamental importance to all cells. By catalysing the ATP-dependent phosphorylation of glucose to yield glucose-6-phosphate, hexokinases control the first committed step of glucose metabolism, thereby sustaining the concentration gradient that permits facilitated glucose entry into cells and initiating all major pathways of glucose utilization. Hexokinases are thus ideally positioned to influence not only the magnitude, but also the direction, of glucose flux within cells (Figure 1 ).
Mammalian cells express multiple hexokinase isoforms
Four highly homologous hexokinase isoforms, encoded by separate genes, have been described in mammalian tissues (Katzen and Schimke, 1965; Sebastian et al., 1997; Wilson, 2003) . Individual isoforms -denoted as HKI, HKII, HKIII and HKIV in the terminology of Katzen and Schimke (1965) -exhibit a number of close structural and functional similarities that have been attributed to a common evolutionary origin (Colowick, 1973; Wilson, 1997a; Cardenas et al., 1998) , but they are also characterized by important differences in kinetic features, regulatory properties, intracellular distribution and patterns of expression (Table 1) 
(UDP-Glc, UDP-GlcNAc) Figure 1 Hexokinases play a central role in cellular glucose metabolism. Hexokinases (HK) catalyse the first obligatory step of glucose metabolism, the ATP-dependent phosphorylation of glucose (Glc) to yield glucose-6-phosphate (Glc-6-P). In addition to maintaining the downhill concentration gradient that permits facilitated glucose entry into cells, this reaction constitutes the first step of all major pathways of glucose utilization, including glycolysis, the pentose phosphate pathway, (PPP) and glycogenesis. As such hexokinases are uniquely positioned to influence the extent and direction of glucose flux within the cell. The PPP represents the principal cellular source of NADPH and plays important roles in redox homeostasis, anabolism and nucleotide synthesis (Rib-5-P, ribulose 5-phosphate). Similarly, glycolysis and glycogenesis play important roles in energy metabolism and storage, respectively. Other important cellular functions, including hexosamine and nucleotide sugar generation for glycosaminoglycan and glycoprotein biosynthesis, also require Glc-6-P as a precursor (UDP-Glc, uridine diphosphate glucose; UDP-GlcNAc, uridine diphosphate N-acetylglucosamine).
suit individual isoforms for distinct metabolic roles within cells (Wilson, 2003) . This makes perfect sense from both a physiologic and a metabolic perspective, insofar as metabolic requirements vary widely not only for individual cell types, but also for a given cell exposed to fluctuating substrate availability, energy demands, environmental stresses, and other external stimuli such as hormones and growth factors. Some specialized functions of individual hexokinase isoforms have already been identified (Postic et al., 2001; Wilson, 2003) , but the overarching rationale for the coexistence of multiple hexokinase isoforms within a single tissue, or within a given cell, remains incompletely defined (Wilson, 2003) . Where examined, most mammalian tissues and cell types, including tumor cells, have been found to express multiple hexokinase isoforms (Katzen and Schimke, 1965; Wilson, 1985; Katzen and Soderman, 1988; Preller and Wilson, 1992; Shinohara et al., 1994; Allen et al., 1998; Riddle et al., 2000; Coy et al., 2002) (RB Robey, unpublished findings). Detailed information regarding isozymic composition, however, is notably lacking for many cell types, which has limited the ability to define unique roles for individual isoforms, as well as their relative biological contributions (Robey, 2003) . The high-affinity isoforms HKI, HKII, and HKIII each have K m values in the micromolar range, are approximately 100 kDa in size, and are characterized by sensitivity to feedback inhibition by their principal reaction product, glucose-6-phosphate. In contrast, HKIV (also referred to as glucokinase or GK) exhibits a relatively low affinity for glucose (K m B6 mM), is approximately half the size of its high-affinity counterparts, and represents the only mammalian hexokinase isoform that is not inhibited by glucose-6-phosphate (Iynedjian, 1993; Wilson, 1995; Postic et al., 2001) . There is marked primary sequence homology between individual N-and C-terminal halves (henceforth, referred to as 'hemidomains') of all three B100 kDa high-affinity isoforms, and the intron-exon organization of the genetic regions encoding these highly conserved hemidomains bear an uncanny resemblance to one another. Analogous comparisons with a number of B50 kDa hexokinases, including GK and several non-mammalian orthologues, have revealed similar conserved structural features. These observations have strongly supported earlier speculation that the larger isoforms originally arose via duplication and tandem ligation of an ancestral B50 kDa hexokinase precursor (Colowick, 1973; Easterby and O'Brien, 1973) . Most recent models have attempted to reconcile differences in sensitivity to glucose-6-phosphate inhibition by suggesting that this common evolutionary precursor was a glucose-6-phosphate sensitive B50 kDa hexokinase akin to starfish or schistosomal hexokinases (Wilson, 1997a; Cardenas et al., 1998) . Subsequent evolutionary divergence, which would appear to be greatest in the aminoterminal hemidomains of the larger isoforms (Cardenas et al., 1998) , has been proposed to explain the distinctive regulatory and kinetic properties of individual isoforms. Of note, the amino-and carboxyl-terminal hemidomains of HKI have each retained the ability to bind both glucose and glucose-6-phosphate at distinct sites (White and Wilson, 1989; Aleshin et al., 1998) , but the catalytic activity of HKI is functionally restricted to its carboxylterminal hemidomain (White and Wilson, 1989; Arora et al., 1993; Tsai, 1999) . The functional topology of HKIII is less well-characterized, but catalytic activity appears similarly restricted to the carboxyl-terminal half (Tsai and Wilson, 1997; Tsai, 1999) . In contrast, both the amino-and carboxyl-terminal hemidomains of HKII possess intrinsic catalytic activity (Ardehali et al., 1996; Tsai and Wilson, 1996; Ardehali et al., 1999) . The corresponding physical assignment of specific regulatory functions to structural regions of individual isoforms is more controversial and has been reviewed elsewhere (Wilson, 1997a; Cardenas et al., 1998) . Glucose-6-phosphate regulatory function, originally predicted to reside at a single site in the amino-terminus of intact HKI (White and Wilson, 1987) , has been shown to represent an intrinsic feature of the carboxylterminal half of this isoform (White and Wilson, 1989; Arora et al., 1993) . To reconcile these findings, it has been suggested that regulatory domains identified in individual hemidomains may reside in a latent or masked form in the intact enzyme (Wilson, 1997a) . Others have suggested that the amino-terminus of HKI is dispensable for both catalytic and regulatory function but could play a role in the modulation of mitochondrial (Wilson, 2003) . The GK kinetic data are adapted from Xu et al. (1995) . All other data are adapted from Wilson (1985 Wilson ( , 2003 or the freely available NCBI Entrez online database (http:// www.ncbi.nlm.nih.gov/). Abbreviations: Glc-6P, glucose -6-phosphate; HK, hexokinase.
hexokinase binding (discussed below) (Arora et al., 1993) . A recent study suggesting that glucose-6-phosphate-mediated release of HKI from mitochondria specifically requires an intact glucose-6-phosphate-binding site in its amino-terminal hemidomain (Skaff et al., 2005) is compatible with such a contention. Interestingly, two discrete glucose-6-phosphate regulatory sites exhibiting markedly different sensitivities to glucose-6-phosphate have been described in the individual halves of intact HKII (Ardehali et al., 1996 (Ardehali et al., , 1999 . Although still speculative, the presence of two independent regulated catalytic sites with markedly different kinetic features has been proposed to equip HKII to retain enzymatic function under conditions inhibitory to other high affinity isoforms (Ardehali et al., 1999) . The ubiquitous HKI isoform appears to be constitutively expressed in most tissues. HKII, which represents the principal regulated isoform in many cell types (Osawa et al., 1995; Riddle et al., 2000; Shinohara et al., 2001; Bryson et al., 2002; Taneja et al., 2004) (RB Robey, unpublished findings) , is also widely expressed and represents the major isoform in insulin-sensitive tissues such as muscle and adipose that account for the bulk of peripheral glucose utilization, as well as in many highly glycolytic cancers (Wilson, 1995; Pedersen et al., 2002) . HKIII exhibits a similarly broad range of expression, but is not the predominant isoform in any tissue in which it has been examined, and the regulation of its expression has been largely unexplored (Wilson, 1985; Cardenas et al., 1998) . The potent feedback inhibition by glucose-6-phosphate that characterizes each of the high-affinity isoforms probably represents one of their most important distinguishing regulatory features. In kinetic terms, the HKI and HKII isoforms closely resemble one another, with HKI exhibiting a higher relative affinity for glucose. An important feature that sets HKI apart from the other glucose-6-phosphateinhibitable isoforms, HKII and HKIII, is reduced sensitivity to feedback inhibition by glucose-6-phosphate in the presence of inorganic phosphate (Table 1) . In contrast, inorganic phosphate directly inhibits both HKII and HKIII, an effect that is additive to glucose-6-phosphate inhibition of these isoforms (Wilson, 1995 (Wilson, , 2003 . Less is known about the kinetic behavior of HKIII than the other high-affinity isoforms, but HKIII exhibits both higher affinity for glucose and lower sensitivity to glucose-6-phosphate inhibition than either HKI or HKII. Interestingly, HKIII is also characterized by substrate inhibition at physiologic concentrations of glucose in vitro, an effect that may be attenuated in vivo by normal intracellular ATP levels (Wilson, 1995) . The features that distinguish HKIII from HKI and HKII (i.e. a lack of mitochondrial localization and a kinetic profile suited to lower substrate concentrations) may serve to expand the effective glucose phosphorylating range of cells co-expressing HKIII with other isoforms (Cardenas et al., 1998) , but a more specific rationale for the evolutionary selection of such features remains obscure. The ability of inorganic phosphate to antagonize glucose-6-phosphate inhibition of HKI has been proposed to suit this isoform for a ubiquitous catabolic role, whereas the additive inhibitory effects of inorganic phosphate and glucose-6-phosphate on HKII and HKIII have been postulated to better equip these isoforms for corresponding anabolic roles (Wilson, 2003) .
Glucokinase exhibits the most restricted pattern of tissue expression, being found primarily in the liver and the endocrine pancreas (Postic et al., 2001) . Glucokinase gene expression is controlled by alternate tissue-specific promoters that account for the existence of distinct pancreatic and hepatic splice variants that differ only in their amino-terminal sequences encoded by separate first exons (Wilson, 1995) . Less is known about the regulation of the hepatic form, but GK, like HKII, is clearly regulated at the level of expression by hormones important for glucose homeostasis, such as insulin (Granner and Pilkis, 1990) . In pancreatic beta cells, GK plays a highly specialized role as a component of the glucose sensing mechanism that regulates insulin release. The relatively high K m for glucose matches the range of optimal enzymatic responsiveness to physiologic glucose concentrations and ideally suits GK for this function. In the liver, the lower affinity for glucose and absence of feedback inhibition by glucose-6-phosphate also ensures that GK can function to promote uptake and utilization in hepatocytes under conditions where glucose is plentiful, but not under conditions where gluconeogenesis and hepatic glucose release are favored (Granner and Pilkis, 1990; Postic et al., 2001 ). Regulation of hexokinase activity is thus highly complex and occurs at multiple levels. Regulation at the level of expression determines the types and amounts of individual hexokinases expressed in a given cell type under a given set of conditions and is of obvious importance. Additional regulatory mechanisms involving intracellular compartmentalization, substrate availability and feedback inhibition have presumably evolved to provide dynamic flexibility in tailoring individual hexokinase responses to widely varying cell requirements and conditions.
The mammalian hexokinase isoforms HKI and HKII physically and functionally interact with mitochondria An important fundamental distinguishing feature of the mammalian HKI and HKII isoforms involves their unique capacity to directly interact with mitochondria, both physically and functionally. This property is not shared by the mammalian HKIII or GK (HKIV) isoforms, or by yeast hexokinases. As such, HKI and HKII are often referred to as mitochondrial hexokinases. The partitioning of hexokinase activity into both soluble and particulate fractions of mammalian tissue extracts has been recognized for over 50 years (Crane and Sols, 1953; Katzen et al., 1970) . It is now known that the particulate fraction can be largely accounted for by specific HKI and HKII binding to the OMM at mitochondrial contact sites, and the interested reader is referred to a comprehensive review by Wilson (Wilson, 1995) for specific details. This binding is both dynamic and regulated (Wilson, 1978) and involves specific interaction between the OMM voltage-dependent anion channel (VDAC) and hydrophobic mitochondrial binding domains found in the amino-terminus of HKI and HKII, but not HKIII or GK (Polakis and Wilson, 1985; Nakashima et al., 1986; Gelb et al., 1992; Pastorino et al., 2002; Majewski et al., 2004a) . Although still incompletely understood, a major landmark in our understanding of the molecular basis of hexokinasemitochondria interaction occurred about 25 years ago when a hexokinase-binding protein isolated from mitochondria (Felgner et al., 1979) was identified as VDAC (Fiek et al., 1982; Linde´n et al., 1982) . Subsequent studies have clearly validated the notion that mammalian VDAC directly participates in the specific binding of mitochondrial hexokinases to the OMM (Nakashima et al., 1986; Vyssokikh et al., 2001; Azoulay-Zohar et al., 2004; Zaid et al., 2005) . Unlike their mammalian counterparts, yeast hexokinases do not bind mitochondria, and yeast mitochondria do not bind hexokinases (Wilson, 1997b) . Experiments utilizing yeast mitochondria isolated from strains expressing orthologous human VDAC isoforms have shown that HKI binding to yeast mitochondria requires the presence of mammalian VDAC isoforms (AzoulayZohar and Aflalo, 1999, 2000) . In these studies, HKI exhibited a higher affinity for the prototypic VDAC1 isoform than for other mammalian VDAC isoforms and suggested specific involvement of VDAC carboxylterminal extramitochondrial domains in this interaction Aflalo, 1999, 2000) . It has also been shown that selective covalent modification (Nakashima et al., 1986; Gelb et al., 1992; Whitesell et al., 2005) or targeted mutation (Zaid et al., 2005) of a specific glutamate residue (E72) selectively inhibits the ability of VDAC to bind hexokinase (Nakashima et al., 1986; De Pinto et al., 1993) . VDAC is responsible for regulating the normal exchange of metabolites critical for mitochondrial function across the OMM and into the IMS where they are then accessible to the specific inner mitochondrial membrane (IMM) transport mechanisms responsible for their uptake into the matrix (Colombini, 2004) . The ability to specifically bind mitochondria distinguishes HKI and HKII from other hexokinase isoforms, as well as other glycolytic enzymes, and is thought to play an important role in hexokinase regulation and function (Anderson et al., 1971; Wilson, 1978; Wilson, 1995) . There is considerable variation in the proportion of hexokinase activity bound to mitochondria in different cell types and tissues, with the majority found in the bound form in some tissues, such as brain and kidney (Crane and Sols, 1953; Parry and Pedersen, 1984) . Mitochondrial hexokinase activity is also increased in many tumors (Bustamante and Pedersen, 1977; Parry and Pedersen, 1983) where it has been reported to correlate with in vivo tumor growth rates (Bustamante et al., 1981) . The dynamic movement of hexokinase between mitochondrial and cytosolic compartments is influenced by a variety of factors that include physiologic concentrations of glucose-6-phosphate, ATP, divalent cations, inorganic phosphate and intracellular pH (Rose and Warms, 1967; Wilson, 1978; Miccoli et al., 1996 Miccoli et al., , 1998 . By providing 'privileged access' to intramitochondrial ATP, mitochondrial localization is thought to confer specific functional advantages to mitochondria-bound hexokinases. Consistent with this view, mitochondrial hexokinases, which bind in a unique tetrameric form (Xie and Wilson, 1990; Beutner et al., 1998; Vyssokikh et al., 1999) , exhibit both increased specific activity and decreased feedback inhibition relative to their soluble monomeric counterparts in the cytosol (Wilson, 1995) . Mitochondrial hexokinases also directly couple the first committed step of glucose metabolism to oxidative phosphorylation, and, during coupled respiration, selectively utilize intramitochondrial ATP for glucose phosphorylation, even if extramitochondrial ATP is available (Arora and Pedersen, 1988; Wilson, 1991, 1992a, b) . ADP generated through this reaction can then be channeled back into the mitochondrion to support oxidative phosphorylation (Gumaa and McLean, 1969) . Regulation of this coupling is thought to occur at the level of mitochondrial hexokinase association through a feedback mechanism involving glucose-6-phosphate, which presumably induces conformational changes that promote hexokinase dissociation from VDAC and the OMM (Wilson, 1973) . Recently, it was shown that, in the case of HKI, this effect appears to specifically require interaction between glucose-6-phosphate and the amino-terminal half of HKI (Skaff et al., 2005) . There is indirect evidence to support the contention that this dynamic, regulated interaction with mitochondrial hexokinases modulates the VDAC open state and influences mitochondrial integrity. A model describing this possibility is depicted in Figure 2 . Like hexokinase, creatine kinase associates with VDAC in multimeric form, but only on the contralateral side of the OMM in the IMS and only when hexokinase is not externally bound (Beutner et al., 1996 (Beutner et al., , 1998 . The recovery of octameric creatine kinase and tetrameric hexokinase in distinct VDAC-containing complexes suggests that hexokinase binding to the extramitochondrial surface and creatine kinase binding to the intramitochondrial surface of VDAC are mutually exclusive and therefore, do not occur simultaneously. When complexed with hexokinase, VDAC is thought to directly interact with the adenine nucleotide translocator (ANT) in the IMM, whereas creatine kinase is physically interposed between VDAC and ANT when hexokinase is not present (Beutner et al., 1996 (Beutner et al., , 1998 . This raises the possibility that when hexokinase is dissociated from the extramitochondrial domain of VDAC, creatine kinase can bind to the intramitochondrial domain of VDAC and thus, may also play a role in the regulation of VDAC closure and apoptosis. As such, hexokinase and creatine kinase may coordinately modulate VDAC activity and VDAC-ANT interaction and thereby influence both the formation and topology of mitochondrial contact sites (Vyssokikh and Brdiczka, 2003) . Clearly, the ability of mitochondrial hexokinases to discriminate between intra-and extramitochondrial ATP pools (elegantly reviewed in (Wilson, 2003) ) supports the concept of metabolic coupling via adenine nucleotide exchange when hexokinases are bound, ostensibly through an open VDAC. The inability of non-binding yeast hexokinase to mimic these effects in the same model also supports this contention. This notion of metabolic coupling importantly underpins a major part of our model of hexokinase-attenuated apoptosis detailed later in this review.
Mitochondrial hexokinases as downstream effectors of growth factor-and Akt-mediated cell survival
One of the first indications that mitochondrial hexokinases might play a role in growth factor-and Aktmediated cell survival came from studies demonstrating decreased mitochondrial hexokinase association following the induction of apoptosis by growth factor withdrawal combined with UV irradiation (Gottlob et al., 2001) . This decrease, which was assessed as the glucose phosphorylating capacity of mitochondria-enriched subcellular fractions, temporally preceded the release of cytochrome c and was not associated with changes in the corresponding glucose phosphorylating capacity of whole cell lysates (Gottlob et al., 2001) . Akt activation, which is known to inhibit apoptosis upstream of cytochrome c release (Kennedy et al., 1999) , antagonized apoptosis-associated hexokinase detachment from mitochondria (Gottlob et al., 2001) . This observation implies that Akt maintains the association of hexokinase with mitochondria and that this association may somehow prevent the release of cytochrome c. These findings have been corroborated by several subsequent studies. First, it has been shown that ectopic HKI or HKII expression mimics the ability of growth factors and Akt to inhibit cytochrome c release and apoptosis (Gottlob et al., 2001; Bryson et al., 2002; Pastorino et al., 2002; Rathmell et al., 2003; Majewski et al., 2004a) . Second, like Akt, mitochondrial hexokinase requires glucose to inhibit apoptosis and cytochrome c release, and the association of hexokinase with mitochondria correlates with the ability of Akt to maintain OMM integrity and inhibit apoptosis (Gottlob et al., 2001; Bryson et al., 2002; Majewski et al., 2004b) . Third, growth factor stimulation of mitochondrial hexokinase association is abrogated in Akt-deficient cells, an effect that is mimicked by pharmacologic inhibition of PI3K in their wild-type counterparts (Majewski et al., 2004a) . Fourth, glucose deprivation, which impairs the ability of Akt to both maintain mitochondrial integrity and inhibit apoptosis, has also been associated with reduced mitochondrial hexokinase association (Majewski et al., 2004b) . Lastly, targeted disruption of hexokinasemitochondria interaction impairs the antiapoptotic and mitochondrial integrity-promoting functions of growth factors and Akt (Majewski et al., 2004a) .
As indicated above, the ability of Akt and hexokinase to inhibit apoptosis is dependent upon the availability of glucose. There is also evidence to suggest that glucose metabolism is required for these effects. The short-term Figure 2 Topology of hexokinase-mitochondria interaction. Hexokinase (HK) directly interacts with and promotes the 'open' configuration of the voltage-dependent anion channel (VDAC) that permits anionic metabolite exchange across the outer mitochondrial membrane (OMM). Functional coupling with oxidative phosphorylation is mediated by ADP-ATP exchange through both VDAC and the adenine nucleotide translocator (ANT) in the inner mitochondrial membrane (IMM). Voltage-dependent anion channel and ANT reportedly interact directly when complexed with hexokinase (left panel), a physical arrangement that is thought to contribute to mitochondrial contact site formation. Dissociation of HK, such as that promoted by glucose-6-phosphate (Glc-6-P) accumulation (right panel), results in a 'closed' VDAC configuration that prevents further adenine nucleotide exchange, thereby uncoupling intra-and extramitochondrial metabolism. Creatine kinase in the IMS also binds to VDAC on the contralateral surface of the OMM and may also contribute to this 'closed' VDAC configuration. This whole process is fully reversible, and HK reassociation following removal of the dissociating stimulus (e.g. following Glc-6-P consumption) permits restoration of metabolite exchange, thereby coupling extramitochondrial glycolysis to intramitochondrial oxidative phosphorylation (see text for details). Figure adapted from Robey and Hay (2005b) , where a detailed depiction of the corresponding topology of the mitochondrial contact sites can also be found.
ability of the phosphorylatable glucose analog 2-deoxyglucose -but not the non-phosphorylatable analog 5-thioglucose -to substitute for glucose in this regard suggests that glucose phosphorylation, vis-a`-vis hexokinase activity, is specifically required (Gottlob et al., 2001) . However, this needs to be directly verified using a catalytically inactive mutant of hexokinase. Other investigators have demonstrated that 2-deoxyglucose-6-phosphate, generated via the action of hexokinase, can be metabolized via the pentose phosphate pathway (PPP) in quantities sufficient to support redox coupling critical for cell survival (Le Goffe et al., 1999 Goffe et al., , 2002 and redox coupling between this pathway and caspase-2 activation has also recently been described (Nutt et al., 2005) , so potential metabolic contributions distal to glucose phosphorylation cannot be excluded (see below).
The physical and functional coupling between hexokinases and mitochondria makes good teleologic sense, insofar as this allows mitochondrial hexokinases ready access to intramitochondrial ATP (Wilson, 1995) . The dynamic regulation of both hexokinase catalytic activity and mitochondrial association by physiologic concentrations of glucose-6-phosphate -and, to a lesser extent, inorganic phosphate, divalent cations, ATP and other biologically relevant metabolites -suggests specific metabolic sensing functions for mitochondrial hexokinases, as well as mechanisms whereby intra-and extramitochondrial metabolism may be coordinated (Wilson, 1995) . The most obvious and physiologically important sensing mechanism involves the principal reaction product, glucose-6-phosphate, which both inhibits mitochondrial hexokinase activity and induces conformational changes in the enzyme that lead to its transient dissociation from VDAC and the OMM (Wilson, 1995) . Intracellular glucose-6-phosphate accumulation resulting from increased glucose uptake and phosphorylation and/or reduced downstream metabolic flux via glycolysis and the PPP can thus, both promote and prolong hexokinase dissociation from mitochondria, thereby potentially sensitizing cells to apoptosis.
The ability to target mitochondrial hexokinase association for selective disruption in intact cells has provided an important tool for examining the specific role of hexokinase binding in the maintenance of OMM integrity. One approach is based upon the observation that certain azoles, and clotrimazole in particular, effectively dissociate hexokinase from mitochondria. The underlying molecular basis of this effect is not known, but it does not appear to involve calcium metabolism or a direct mitochondrial effect of these agents (Penso and Beitner, 1998; Azoulay-Zohar and Aflalo, 2000) . Another, more specific approach is based upon the observation that a chimeric protein containing the 15 amino-terminal hydrophobic residues of HKI binds to mitochondria and can be specifically displaced by the addition of increasing amounts of HKI (Gelb et al., 1992) . Subsequent studies have demonstrated that incubating cells with cell-permeable peptides corresponding to or containing the amino-terminal hydrophobic domains of mitochondrial hexokinases are capable of competitively displacing endogenous hexokinases from mitochondria in intact cells and sensitizing them to apoptosis at a level upstream of cytochrome c release (Pastorino et al., 2002 (Pastorino et al., , 2005 Majewski et al., 2004a) (N Hay and RB Robey, unpublished observations). So how do mitochondrial hexokinases inhibit apoptosis and maintain OMM integrity? Several lines of evidence suggest that mitochondrial hexokinases could intervene in the classical apoptotic cascade by restricting the accumulation and oligomerization of Bax and Bak at the OMM. In vitro studies involving isolated functioning mitochondria have shown that recombinant HKII binding prevents recombinant Bax from binding and releasing cytochrome c, whereas forced detachment of hexokinase from mitochondria has the opposite effect and increases the ability of Bax to induce apoptosis in intact cells (Pastorino et al., 2002) . Ectopic cellular expression of active forms of mitochondria-binding hexokinases has also been shown to impair the ability of activated Bid (tBid) (Majewski et al., 2004b) or Bax (Pastorino et al., 2002) to induce apoptosis. Taken together with the inability of Akt activation to prevent Bak oligomerization in the absence of glucose (Majewski et al., 2004b), these results suggest that Bax or Bak oligomers may share a common binding site with mitochondrial hexokinases on the OMM. Hexokinase binding could thus physically hinder accumulation and oligomerization of Bax or Bak and inhibit their ability to promote cytochrome c conducting conduit formation in the OMM. These interactions are probably localized to mitochondrial contact sites where the OMM and IMM converge, as they are enriched in both hexokinase and the charged phospholipid cardiolipin (Ardail et al., 1990; Wilson, 2003) . Cardiolipin is a reported requirement for mitochondrial tBID localization and Bax/Bakmediated cytochrome c release, and its OMM presence is spatially restricted to these sites (Lutter et al., 2000 (Lutter et al., , 2001 Epand et al., 2002; Kuwana et al., 2002) . Hexokinases also bind as tetramers to the OMM in close proximity to, or in direct contact with VDAC at mitochondrial contact sites (Xie and Wilson, 1990; Beutner et al., 1998) , so the local presence of large hexokinase-containing complexes may sterically prevent Bax and Bak access to their preferred cardiolipinenriched binding sites. A demonstrated requirement for cardiolipin in Bax/Bak-mediated macromolecular diffusion through OMM pores (Kuwana et al., 2002) is compatible with this contention. By virtue of the dynamic nature of hexokinase-mitochondria association under normal physiological conditions, Bax and Bak access to these sites would be temporally restricted to intervals when hexokinases are unbound. Hence, Bax and Bak binding would be directly affected by the kinetics of mitochondrial hexokinase binding, particularly binding affinity and on-off rates. In the absence of growth factors, hexokinase dissociation will be prolonged, enabling activated Bak or Bak to accumulate at these sites. As growth factor withdrawal also activates Bax and Bak, hexokinase in this scenario will no longer be able to hinder oligomerized Bax or Bak binding and permeabilization of the OMM. This is schematically depicted in Figure 3 . However, it also appears that prolonged hexokinase dissociation from mitochondria can still induce OMM permeabilization in the absence of Bax and Bak (Majewski et al., 2004a) . This suggests the existence of an additional mechanism by which hexokinase dissociation facilitates OMM permeablization.
Despite general resistance to apoptosis, cells doubly deficient for Bax and Bak release cytochrome c from mitochondria and undergo apoptosis in response to calcium-dependent apoptotic stimuli following artificial correction of the intrinsic calcium storage defect in these cells . Cytochrome c release in this case likely results from calcium-dependent permeability transition pore formation, followed by osmotic swelling of the mitochondrial matrix and OMM rupture (Desagher and Martinou, 2000) . In contrast, hexokinase dissociation from mitochondria induces apoptosis in Bax-and Bak-deficient cells in a calcium-independent manner (Majewski et al., 2004a) . Unlike Bcl-2 overexpression or combined Bax and Bak deficiency, activated Akt is unable to inhibit calcium-dependent apoptosis. This alternate mitochondrial hexokinasedependent mechanism ostensibly involves the maintenance of mitochondrial homeostasis via regulated metabolite exchange into and out of mitochondria and can be attributed to dynamic mitochondrial hexokinase interaction with VDAC and regulation of OMM metabolite exchange (Figure 3) . Deregulation of VDAC function has been suggested to follow apoptotic insults. Sustained VDAC closure following growth factor withdrawal (Vander Heiden et al., 2000; Gottlob et al., 2001 Gottlob et al., , 2002 may be a consequence of prolonged mitochondrial hexokinase dissociation and may lead to both hyperpolarization and IMM remodeling (Gottlieb et al., 2003;  Majewski et al., 2004a) . These changes, which are opposed by Akt (Gottlob et al., 2001) , can lead to mitochondrial matrix swelling and OMM rupture, resulting in the non-selective release of proapoptotic mitochondrial proteins, including cytochrome c (Figure 3) (Vander Heiden et al., 1999) . VDAC closure and permeability transition pore formation thus represent independent mechanisms for cytochrome c release via OMM compromise that phenotypically correspond to those proposed before the availability of genetic evidence that Bax and Bak are required for mitochondrial apoptosis (Desagher and Martinou, 2000) . Proapoptotic signals are not effectively transduced to mitochondria in the absence of Bax and Bak, but forced hexokinase dissociation from mitochondria can still impair mitochondrial integrity and cytochrome c release in Bax-and Bak-deficient cells, albeit without the same efficiency as in the presence of Bax and Bak. In the absence of signals to sustain Akt-dependent hexokinase binding, certain apoptotic stimuli, such as UV irradiation, remain capable of promoting cytochrome c release and apoptosis in the absence of Bax and Bak. However, the kinetics of cytochrome c release and apoptosis are markedly delayed (Majewski et al., 2004a) . These responses are also not suppressible by Bcl-2 and, in principle, could contribute to apoptotic death in the absence of Bcl-2 proteins.
It should be noted that VDAC closure in studies such as those described above is inferred from mitochondrial phosphocreatine accumulation in intact cells and thus may be influenced by the presence or absence of external sources of creatine such as serum. The cellular phosphocreatine circuit serves important high-energy phosphate buffering and transport functions that involve the action of creatine kinase in both the mitochondrial IMS and in the cytosol. Creatine kinase can catalyse the ATP-dependent phosphorylation of creatine, as well as the reverse ADP-dependent dephosphorylation of phosphocreatine. The reaction equilibrium strongly favors ATP and creatine formation, except where local ATP concentrations are high, as in the IMS of actively respiring mitochondria. When VDAC is open, phosphocreatine generated in the IMS passes directly into the cytosol, where cytosolic creatine kinase immediately and quantitatively catalyses the reverse reaction to yield creatine and ATP. However, when VDAC is closed, phosphocreatine accumulates in the IMS. The ability of ANT to transport ATP into the IMS while VDAC is closed is an implicit requirement for this accumulation. As already detailed, creatine kinase associates with the intramitochondrial aspect of VDAC and, like hexokinase, may modulate the VDAC open state and therefore, regulate apoptosis. Again, this interpretation relies heavily upon the assumption that phosphocreatine accumulation can represent a valid marker of VDAC closure in intact cells, so other potential explanations for these changes cannot be fully excluded.
Despite experimental observations supporting the models depicted in Figures 2 and 3 , other investigators have recently suggested that hexokinase-mediated VDAC closure, rather than VDAC opening, may underlie the ability of hexokinases to inhibit apoptosis (Azoulay-Zohar et al., 2004; Zaid et al., 2005) . This fundamentally different interpretation was inferred from the ability of HKI to decrease the in vitro conductivity of purified VDAC reconstituted into planar lipid bilayers by approximately 70% and is based upon the assumption that cytochrome c is released via VDAC (AzoulayZohar et al., 2004) . This effect required an intact HKI amino-terminus containing the putative mitochondrial binding domain, was specific for a single bilayer interface, and was antagonized by glucose-6-phosphate (Azoulay-Zohar et al., 2004; Zaid et al., 2005) , consistent with an effect specifically mediated by hexokinase-VDAC interaction. The corresponding ability of ectopic HKI to prevent calcium-induced swelling of, and cytochrome c release by, isolated mitochondria, as well as staurosporine-induced apoptosis in intact U-937 cells and vascular smooth muscle cells, was interpreted as a consequence of hexokinase-induced VDAC closure preventing permeability transition pore formation (Azoulay-Zohar et al., 2004; Zaid et al., 2005) . Interestingly, VDAC1 overexpression induced apoptosis in the same model, an effect that was antagonized by HKI co-expression. HKI was unable, however, to inhibit apoptosis induced by a VDAC1 mutant lacking a critical glutamate residue (E72Q) required for hexokinase binding (Zaid et al., 2005) . The voltage-dependent conductance of this channel was unaffected by this mutation (Zaid et al., 2005) , consistent with previous observations that selective chemical modification of this glutamate residue (E72) by dicyclohexylcarbodiimide (DCCD) inhibits the ability of VDAC to bind hexokinase (Nakashima et al., 1986; Gelb et al., 1992; Whitesell et al., 2005) without affecting intrinsic channel function (De Pinto et al., 1985) . The mechanism by which hexokinase inhibits apoptosis as inferred from these studies seemingly contradicts the work described earlier. The observation that hexokinase binding induces the in vitro closure of VDAC is inconsistent with evidence from studies of intact mitochondria suggesting that mitochondrial hexokinases selectively utilize intramitochondrial ATP to phosphorylate glucose and directly couple glycolysis to oxidative phosphorylation (Arora and Pedersen, 1988; Wilson, 1991, 1992a, b; Laterveer et al., 1993; Wilson, 1995, 1998; Hashimoto and Wilson, 2000) . Thus, bound hexokinase requires access to ATP exported via VDAC. However, if hexokinase binding closes VDAC to anion exchange, ATP cannot be exported for utilization by mitochondrial hexokinase. The reported ability of mitochondria-binding, but not non-binding, forms of hexokinase to reduce mitochondrial reactive oxygen species generation through adenine nucleotide recycling (Seixas da-Silva et al., 2004) further supports the notion that hexokinase-mitochondria interaction involves an open metabolite exchange conduit, ostensibly involving VDAC. Perhaps these seemingly contradictory findings can be reconciled, in part, if the observed in vitro conductance changes do not correspond to the capacity for metabolite exchange in intact mitochondria. Regardless, according to these studies, hexokinase binding to VDAC should inhibit apoptosis induced by mitochondrial calcium overload, which results in permeability transition pore formation. This is inconsistent, however, with the observation that Akt, unlike Bcl-2, cannot inhibit apoptosis in response to endoplasmic reticulum calcium release by thapsigargin (Majewski et al., 2004a) .
How do growth factors and Akt mediate hexokinase-mitochondria interaction?
It has been clearly demonstrated that growth factors induce hexokinase translocation to mitochondria, an effect that is impaired in Akt-deficient cells. However, the mechanism by which Akt affects this translocation is not known. In principle, Akt can influence a variety of metabolic processes, and thereby indirectly modulate hexokinase-mitochondria interaction. For example, glucose deprivation reduces hexokinase interaction with mitochondria (Majewski et al., 2004b) , so Akt-increased glucose transporter expression and membrane targeting could help maintain intracellular glucose levels favoring hexokinase-mitochondria interaction. Compatible with such a notion, one report has suggested that the prosurvival benefits of hexokinase overexpression may be enhanced by GLUT1 overexpression (Rathmell et al., 2003) . Akt may also promote hexokinase-mitochondria interaction by limiting glucose-6-phosphate accumulation through enhancement of its downstream utilization via glycolysis and the PPP. As a kinase, Akt could also directly or indirectly phosphorylate targets that affect the interaction between hexokinase and its mitochondrial receptor VDAC. Although putative Akt phosphorylation motifs can be found in HKII, it has not yet been demonstrated that Akt can directly phosphorylate mitochondrial hexokinases or that such modifications impact hexokinase-mitochondrion interaction. In principle, Akt could also indirectly influence this interaction through Aktmediated changes in the activity of downstream effectors capable of modifying hexokinase or VDAC in a manner that influences their interaction. Such a demonstration has not been made for hexokinase, but it has been suggested that GSK3b, which is phosphorylated and inhibited by Akt, can disrupt mitochondrial hexokinase association via phosphorylation of a putative hexokinase docking site on VDAC (Pastorino et al., 2005) . This site is in close proximity to the critical glutamate residue covalently modified by DCCD and suggests at least one mechanism whereby Akt, through direct phosphorylation and inactivation of GSK3b, could augment mitochondrial hexokinase interaction and promote cell survival. Although potentially at variance with the reported ability of lithium, a known pharmacologic inhibitor of GSK3b, to dissociate hexokinase from mitochondria in cultured melanoma cells (Penso and Beitner, 2003) , the possibility of superimposed GSK3b-independent dissociating effects of lithium cannot be presently excluded.
Potential antiapoptotic effects of metabolic channeling through the pentose phosphate pathway Several reports have suggested antiapoptotic roles for the PPP (Tian et al., 1999; Fico et al., 2004) . As the principal cellular source of the reduced forms of both nicotinamide adenine dinucleotide phosphate (NADPH) and glutathione (GSH), PPP flux plays a major role in cellular redox homeostasis and suggests a non-exclusive alternate mechanism whereby glucose metabolism can contribute to cell survival (Figure 4) . The generation of glucose-6-phosphate is required for entry into the PPP (Figure 1) . Thus, glucose phosphorylation by hexokinase could gate flux through this pathway and thereby directly contribute to both cellular redox status and resistance to oxidant-mediated cell death (Le Goffe et al., 1999 Tian et al., 1999; Kurata et al., 2000) . Glucose-6-phosphate dehydrogenase (G6PDH) activity is rate-limiting for PPP flux and is required for NADPH generation via this route. Physiologic levels of NADPH normally inhibit G6PDH, so PPP flux is dependent upon deinhibition by NADPH consumption and possibly also reduced glutathione accumulation (Eggleston and Krebs, 1974) . Thus, NADPH consumption via coupled metabolism and/or oxidant stress can relieve the feedback inhibition of cytosolic G6PDH that is normally observed under physiologic conditions (Eggleston and Krebs, 1974) , thereby enhancing PPP flux.
Recently, a novel link between PPP flux and the apoptotic cascade was reported (Nutt et al., 2005) . 
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Figure 4 Glucose-6-phosphate generation by hexokinases can gate flux through the pentose phosphate pathway and influence NADPH-coupled processes that directly impact cell survival, including glutathione peroxidase (GSH-Px)-dependent detoxification of peroxides (upper part of figure) and calcium-calmodulin kinase II (CaMKII)-dependent caspase-2 inactivation (lower part of figure) . NADH/NADPH serves as an important redox couple for many important biochemical reactions. The rate-limiting enzyme of the pentose phosphate pathway, glucose-6-phosphate dehydrogenase (G6PDH), is coupled through NADH/NADPH to the enzymatic reduction of glutathione (GSSG, oxidized glutathione; GSH reduced glutathione) by glutathione reductase (GSH-R). This reaction importantly provides GSH for the detoxification of peroxides by GSH-Px. In a similar manner, G6PDH is also coupled to CaMKII activation, which results in the phosphorylation and inactivation of caspase 2 (see text for details).
An additional important function of the pentose phosphate pathway involves nucleotide and nucleic acid biosynthesis important for cellular proliferation.
It was found that glucose-6-phosphate addition to Xenopus egg extracts inhibits cytochrome c release and caspase activation. In Xenopus oocytes and eggs, which are nutritionally self-sufficient, hexokinase activity is reportedly low and glucose-6-phosphate is largely derived from gluconeogenesis using yolk proteins as a source of amino acid substrates. The principal metabolic fates of glucose-6-phosphate involve glycogenesis and, to a lesser extent, PPP flux, but only limited glycolysis. Thus, the demonstrated ability of exogenous glucose-6-phosphate to inhibit mitochondrial cytochrome c release and caspase activation, and the corresponding ability of exogenous NADPH to mimic these effects, suggested an antiapoptotic role for metabolic channeling through the PPP. Consistently, PPP inhibition induced cytochrome c release and apoptosis in Xenopus egg extracts and oocytes. It was subsequently shown that NADPH leads to the specific inhibition of caspase-2 via phosphorylation of its prodomain. It appears that NADPH activates CaMKII, which phosphorylates a serine residue in the prodomain of caspase-2 and thereby inhibits its activity (Nutt et al., 2005) . Whether or not gluconeogenesisderived glucose-6-phosphate can serve a similar role in tissues such as the liver remains to be examined. Caspase-2 is activated by cellular stress, DNA damage and trophic factor deprivation (Lassus et al., 2002; Tinel and Tschopp, 2004; Zhivotovsky and Orrenius, 2005; Tu et al., 2006) and acts upstream of mitochondria through the activation of 'BH3-only' proteins. It has been shown that caspase-2 can cleave and activate Bid (Guo et al., 2002; Lassus et al., 2002; Robertson et al., 2002; Wagner et al., 2004) and that its proapoptotic activity is dependent on Bid (Gao et al., 2005) . Thus, it could well be that mitochondrial hexokinases, in addition to their ability to inhibit apoptosis via direct interaction with mitochondria, also maintain the integrity of mitochondria by inhibiting caspase-2 activation. Associated increases in hexokinase activity and PPP flux in vivo (Sochor et al., 1979) and in cultured mammalian cells Rathmell et al., 2003) are compatible with such a contention.
The potential ability of other ATP-dependent phosphotransferases to substitute for mitochondrial hexokinases in preventing apoptosis Glucokinase It is widely accepted that GK, which lacks a putative hydrophobic amino-terminal mitochondrial binding domain, is incapable of binding mitochondria in the liver (Rose and Warms, 1967; Wilson and Felgner, 1977; Ureta et al., 1983; Arora and Pedersen, 1988; MalaisseLagae and Malaisse, 1988; Shinohara et al., 1997; Wilson, 2003; Bustamante et al., 2005) . However, a recent report of direct interaction between the proapoptotic 'BH3-only' protein Bad and GK in liver cells has been interpreted as suggestive of interplay between apoptotic proteins and glucose metabolism in the liver reminiscent of that described for mitochondrial hexokinases in other cell types (Danial et al., 2003) . In this report, GK was identified as a nominal component of Bad-containing mitochondrial protein complexes in the livers of wild-type, but not Bad-deficient, mice, and it was suggested that Bad could influence glucose metabolism in the liver by targeting GK to liver mitochondria. Ultra rapid exhaustion of the corresponding enzymatic activity under non-limiting reaction conditions, however, is strongly suggestive of an artifactual origin for these changes. In the absence of GK-specific kinetic data or controls to establish ATP or glucose dependence (Iynedjian, 1993) , the biochemical evidence for mitochondrial GK association should probably be interpreted with caution, a caveat reinforced by the subsequent inability of another group to confirm mitochondrial GK activity in the same model (Bustamante et al., 2005) . Thus, in keeping with earlier reports, endogenous GK does not appear to associate with liver mitochondria at levels detectable by conventional enzymatic assays. It bears noting, however, that glucose deprivation clearly inhibited Bad phosphorylation and increased Badmediated apoptosis in these studies (Danial et al., 2003) , suggesting that coupling between glucose and the apoptotic machinery may occur at another level. The role of GK in apoptosis was not addressed, but even in the absence of bona fide direct mitochondrial interaction, GK could theoretically inhibit hepatocyte or beta cell apoptosis through glucose-6-phosphate generation and PPP flux-coupled caspase-2 inactivation.
Glycerol kinase
Although GK does not appear to meaningfully interact with mitochondria, other ATP-dependent phosphotransferases capable of interacting with VDAC could potentially substitute for mitochondrial hexokinase in the modulation of VDAC and promotion of cell survival (Robey and Hay, 2005b) . For example, glycerol kinase, like mitochondrial hexokinases, is known to associate with VDAC at the OMM, and it has been proposed that these enzymes compete for the same binding site(s) (Fiek et al., 1982; Ö stlund et al., 1983) . Reciprocal regulation of glycerol kinase and hexokinase binding to mitochondria in the same system (Fiek et al., 1982; Ö stlund et al., 1983) is not suggestive of redundant metabolic coupling functions, but it is still not unreasonable to speculate that glycerol kinase -or, at least in principle, other VDAC-interacting cytosolic ATP-dependent phosphotransferases -could functionally substitute for mitochondrial hexokinases in modulating VDAC-mediated metabolite exchange across the OMM and promoting cell survival. To our knowledge, these possibilities have not been specifically examined. This could be particularly important, however, in hepatocytes or beta cells exhibiting limited or no appreciable endogenous mitochondrial hexokinase expression or binding (Wilson, 1995; Bustamante et al., 2005) .
Mitochondrial hexokinases and cancer
The classic, and arguably most profound, biochemical phenotype associated with cancer cells involves a fundamental metabolic shift to glycolysis irrespective of oxygen availability (Warburg, 1956; Dang and Semenza, 1999) . This phenotype suggests an obvious survival advantage for cancer cells in hypoxic tumor microenvironments, particularly rapidly proliferating cells in tumors with growth rates that outpace angiogenesis and the development of new blood vessels. Increases in mitochondrial hexokinase expression, binding, and activity are known to contribute to the highly glycolytic tumor phenotype. These changes also constitute the underlying molecular basis for using 2-fluoro-2-deoxyglucose positron emission tomography to diagnose and stage cancers (Smith, 2001) . It is therefore easy to envision that the adaptive survival functions attributed to Akt-hexokinase axis function in 'normal' cells may have a maladaptive counterpart in cancer that can be exploited for therapeutic purposes. Glucose metabolism is of fundamental importance to all cells, but tumor cells typically exhibit a much greater dependence upon glycolytic energy metabolism than their normal counterparts. The ubiquitous importance of these processes seemingly precludes the indiscriminate disruption of energy metabolism as a viable approach to the selective targeting of cancer cells for destruction, but inherent metabolic differences could potentially be exploited to develop adjuvant interventions to slow tumor growth rates or increase the relative susceptibility of cancer cells to both existing and emerging therapies. Clearly, a better understanding of the pathobiology associated with tumor metabolism is needed to direct such efforts, but titrated inhibition of hexokinase activity and targeted disruption of hexokinase-mitochondria interaction represent two conceptually appealing general approaches to these ends (Robey and Hay, 2005a) .
Akt hyperactivation is one of the most frequently demonstrable abnormalities in human cancers (Hay, 2005) , so inhibition of hexokinase activity and/or interaction with mitochondria represent attractive potential therapeutic approaches to cancer. This could be particularly effective for tumors derived form tissues that do not normally express mitochondrial hexokinases. The most studied and profound example is hepatocellular carcinoma, in which HKII expression and activity are markedly elevated relative to normal hepatocytes in which mitochondrial hexokinases are largely undetectable (Bustamante et al., 1981; Mathupala et al., 1997; Shinohara et al., 1997) .
The mammalian target of rapamycin (mTOR) is a major downstream effector of Akt (Hay and Sonenberg, 2004) that is emerging as an important player in cancer and represents a major therapeutic target in a number of ongoing clinical trials for cancer (Vignot et al., 2005) . However, rapamycin derivatives, which are used in these clinical trials to inhibit mTOR, are also activating Akt owing to release from a negative feedback loop normally operating by mTOR activation to restrict Akt activity. Thus, simultaneous targeting of both Akt and mTOR has been advocated to obviate unwanted increases in Akt activation resulting from disruption of the normal negative feedback regulatory loop between mTOR and Akt (Hay, 2005) . Another approach could involve the identification of common downstream mediators of Akt and mTOR action that can be specifically targeted to modulate their contributions to tumorigenesis and progression (Robey and Hay, 2005a) . The dependence of mTOR activity upon both glucose and ATP availability (Inoki et al., 2003) and the observation that inhibition of mTOR decreases glycolytic enzyme expression, including hexokinase, in Akt-dependent tumor cells (Majumder et al., 2004) , suggests the potential use of hexokinase inhibitors to this end. The ability of Akt to activate mTOR, is at least partly dependent upon maintenance of cellular energy homeostasis (HahnWindgassen et al., 2005) , which further underscores the potential utility of targeting hexokinases and cellular energy metabolism for cancer therapy. Interestingly, even before their currently appreciated role in apoptosis, targeting mitochondrial hexokinases was considered as a therapeutic approach for cancer (Oudard et al., 1995) . More recently, the pharmamceutical industry has begun to explore approaches to alter hexokinase activity and localization for cancer therapy (Robey and Hay, 2005a) . Clearly, the ability to selectively disrupt mitochondrial hexokinase expression, activity, and compartmentalization could have profound implications for cancer therapy. However, a better understanding of the mechanisms governing HK expression, localization, and function is needed, and the relative contributions of individual isoforms and upstream regulators needs to be better defined before the therapeutic potential of hexokinase modulation can be fully realized. Maneuvers targeting metabolism distal to hexokinase may also have potential utility, particularly modulation of cellular redox status by controlling PPP flux.
Conclusions
In this review, we have summarized the accumulating evidence for a novel regulatory role for mitochondrial hexokinases in mammalian cell apoptosis. Through their physical and functional interaction with the OMM, these enzymes maintain mitochondrial integrity and prevent the release of proapoptotic IMS proteins. It remains to be determined, however, whether hexokinases can also promote mitochondrial integrity by channeling glucose flux through the PPP and NADPH-coupled caspase-2 inhibition. Additional work is needed to define specific mechanisms by which growth factors and Akt regulate hexokinase-mitochondria interaction and the role that glucose metabolism plays in this interaction.
